BIOLASE (BIOL) Stock Price, News & Analysis

Company Overview

BIOLASE, Inc. (NASDAQ: BIOL) is a medical device company specializing in the design, development and manufacture of laser systems for dentistry. The company’s laser platforms enable minimally invasive dental procedures, combining laser energy with water spray to perform both hard‐tissue and soft‐tissue applications. By integrating advanced laser technology into routine dental care, BIOLASE aims to improve patient comfort, reduce the need for anesthesia and shorten procedure times.

The company’s flagship products include the Waterlase® family of erbium lasers and the Epic™ series of diode lasers. Waterlase systems are indicated for a wide range of applications, including cavity preparation, bone surgery, endodontics, periodontal therapy and oral surgery. Epic diode lasers are used primarily for soft‐tissue procedures such as gum recontouring, pain management and bacterial reduction. BIOLASE also offers a comprehensive portfolio of handpieces, tips and accessories to support clinical workflows and practice growth.

Founded in 1984 and headquartered in Irvine, California, BIOLASE has established a global distribution network that spans North America, Europe, Asia and other international markets. The company works with dental equipment dealers, group purchasing organizations and strategic partners to expand market reach and provide training and support to dental professionals. BIOLASE’s research and development efforts are focused on enhancing laser performance, broadening procedural indications and integrating digital dentistry solutions.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.0010 to $0.0125
• 52-Week Range: N/A
• Volume: 55,436 shs
• Average Volume: 2.58 million shs
• Market Capitalization: $581 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.40
• Consensus Rating: Buy

BIOLASE Stock Analysis - MarketRank™

BIOLASE scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

BIOLASE has a consensus price target of $0.40, representing about ∞ upside from its current price of $0.00.

Amount of Analyst Coverage

BIOLASE has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BIOL.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BIOLASE does not currently pay a dividend.

Dividend Growth

BIOLASE does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BIOL.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.38

News Sentiment

BIOLASE has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BIOLASE this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BIOLASE insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.27% of the stock of BIOLASE is held by insiders.

Percentage Held by Institutions

Only 8.79% of the stock of BIOLASE is held by institutions.

BIOL Stock Analysis - Frequently Asked Questions

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) released its quarterly earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share for the quarter, topping analysts' consensus estimates of ($75.00) by $25.00. The medical technology company earned $9.53 million during the quarter. BIOLASE had a negative net margin of 41.65% and a negative trailing twelve-month return on equity of 1,782.73%.

When did BIOLASE's stock split?

Shares of BIOLASE reverse split before market open on Friday, July 28th 2023.The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BIOLASE investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), SNDL (SNDL), Zomedica (ZOM), NIO (NIO), Exela Technologies (XELA) and Ocugen (OCGN).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Dental equipment & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BIOL
• Previous Symbol: NASDAQ:BLTI
• CIK: 811240
• Web: www.biolase.com
• Phone: (949) 361-1200
• Fax: 949-273-6677
• Employees: 160
• Year Founded: 1987

Price Target and Rating

• Average Price Target for BIOLASE: $0.40
• High Price Target: $0.40
• Low Price Target: $0.40
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.63 million
• Net Margins: -41.65%
• Pretax Margin: -41.56%
• Return on Equity: -1,782.73%
• Return on Assets: -55.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $48.83 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,407,000
• Free Float: 33,317,000
• Market Cap: $581 thousand
• Optionable: Not Optionable
• Beta: 0.67